IOLCP revenue rises 11.5% YoY to Rs. 2,319.1 crore in FY26
Company’s EBITDA grew 29.3 per cent to Rs. 290.4 crore, while PAT rose 36.4 per cent to Rs. 137.7 crore
Company’s EBITDA grew 29.3 per cent to Rs. 290.4 crore, while PAT rose 36.4 per cent to Rs. 137.7 crore
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
Solutions designed to help clinicians reduce administrative burden, improve diagnostic accuracy, and spend more time with patients
Dr. Upadhyay brings over 25 years of global leadership experience across life sciences, regulated manufacturing, diagnostics, and research-led environments
The global diagnostics supplier said the multi-phase expansion aims to deliver more than 60 commercially available recombinant antigen products by 2030
Union health ministry secretary Punya Salila Srivastava lauds HLL’s six decades of contribution to public healthcare and social development
Deployment aims to improve serialization efficiency by 45% and enhance regulatory compliance across global export markets
Growth driven by strong performance across Sugar Free, RiteBite Max Protein, Everyuth, Glucon-D and Nutralite portfolios
Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
Subscribe To Our Newsletter & Stay Updated